Leverette (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol provides estrogenic activity while levonorgestrel supplies progestogenic activity; together they suppress the hypothalamic‑pituitary‑ovarian axis, inhibit the LH surge, prevent ovulation, thicken cervical mucus and modify the endometrium, creating conditions unfavorable for fertilisation and implantation.

The specific dosing regimen for Leverette is determined by the prescribing healthcare professional and follows the standard 21‑day active tablet cycle followed by a hormone‑free interval, as indicated in the product labeling.

Leverette is contraindicated during pregnancy because it is intended to prevent conception; if pregnancy occurs, the product should be discontinued. Use during breastfeeding should be discussed with a physician, as hormonal contraceptives may affect milk production.

To request Leverette, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leverette contains the widely used dose combination of ethinylestradiol and levonorgestrel, offering efficacy comparable to other second‑generation combined pills. Its safety profile, side‑effect spectrum and dosing schedule are similar to alternatives such as microgynon or levlen, with choice often guided by individual tolerance and risk factors.

Store Leverette tablets at ambient temperature, below 25 °C, in the original blister pack, protected from moisture, light and excessive heat. Keep out of reach of children and do not use after the expiration date.

Leverette is taken orally, usually one tablet each day at the same time, for 21 consecutive days followed by a 7‑day hormone‑free interval during which withdrawal bleeding occurs. Patients should follow the prescribing information and consult their healthcare provider for any missed doses.

The most serious risks include venous or arterial thromboembolism, myocardial infarction, stroke, and severe hypertension. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before initiating therapy.

Leverette is contraindicated in women who are pregnant, have known or suspected breast cancer, have active liver disease, have a history of thromboembolic disorders, are over 35 and smoke, or have uncontrolled hypertension. It should also be avoided in individuals with known hypersensitivity to any component of the product.